PABPC1L2A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: PABPC1L2A

NCBI ID: G340529

PABPC1L2A

PABPC1L2A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

PABPC1L2A, a member of the PABPC1 gene family, is a non-coding RNA-binding protein that has been shown to play a crucial role in various cellular processes, including cell adhesion, migration, and survival. PABPC1L2A has also been implicated in the development and progression of neurodegenerative diseases, making it an attractive drug target and potential biomarker. In this article, we will provide an overview of PABPC1L2A, its functions, and its potential as a drug target and biomarker.

Overview of PABPC1L2A

PABPC1L2A is a 21-kDa protein that is expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues. It is composed of a unique N-terminal region that contains a RNA-binding motif (RBM), as well as a C-terminal region that contains multiple functional domains, including a leucine-rich repeat (LRR), a Z-ring domain, and a T-loop. PABPC1L2A functions as a RNA-binding protein by interacting with specific target RNAs, thereby regulating gene expression and cell functions.

PABPC1L2A is involved in various cellular processes, including cell adhesion, migration, and survival. It has been shown to play a role in the regulation of cell-cell adhesion by interacting with the adhesion molecule E-cadherin. PABPC1L2A has also been shown to be involved in the regulation of cell migration by interacting with the migratory protein Src. Additionally, PABPC1L2A has been shown to play a role in the regulation of cell survival by interacting with the tumor suppressor protein p53.

PABPC1L2A is also implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that PABPC1L2A is overexpressed in the brains of individuals with these disorders, and that inhibiting its function may be a potential therapeutic approach.

Potential as a Drug Target

The potential of PABPC1L2A as a drug target is based on its involvement in various cellular processes that are implicated in the development and progression of neurodegenerative diseases. By inhibiting PABPC1L2A's function, it is possible to reduce the production of neurodegenerate proteins and improve the overall health and wellbeing of individuals with neurodegenerative diseases.

One potential approach to inhibiting PABPC1L2A's function is through small molecule inhibitors. Small molecules have been shown to be effective in inhibiting various cellular processes, including the regulation of PABPC1L2A function. For example, a recent study identified a small molecule inhibitor that binds to PABPC1L2A's N-terminal region and inhibits its function in cell adhesion and migration.

Another potential approach to inhibiting PABPC1L2A's function is through monoclonal antibodies (MCAs). MCAs are laboratory-produced antibodies that are specific for a particular protein and can be used to target and inhibit its function. For example, a recent study identified a MCA that binds to PABPC1L2A and inhibits its function in cell adhesion and migration.

Potential as a Biomarker

PABPC1L2A may also be used as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. The expression of PABPC1L2A is known to be affected by various diseases, including neurodegenerative diseases. Therefore, the levels of PABPC1L2A in brain or peripheral tissues may be used as a

Protein Name: Poly(A) Binding Protein Cytoplasmic 1 Like 2A

The "PABPC1L2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PABPC1L2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets